Query
Find articles
Pick a keyword, optionally a second one to combine it with (and, or, either but not both, or but not), then narrow the articles down by text, source and time range. Keywords update the results right away; filters apply with their button.
Query
How they overlap
Of the articles on each keyword in the last 7 days, with the same text and sources, how many also mention the other. Per lean: the share of its outlets' articles on clinical trial that mention vaccine.
66.7% of the 3 articles on clinical trial also mention vaccine, as do 14.3% of the 14 articles on vaccine.
- Left-leaning2 of 2 articles
- 100.0%
- Least biasedno article on clinical trial
- –
- Right-leaning0 of 1 article
- 0.0%
Who picked it up when
The Guardian mentioned it first (Oct 21, 2026, 1:18 PM EDT). No least biased outlet mentioned it. No right-leaning outlet mentioned it.
One row per source with a matching article, from the most left-leaning on top: a dot for each article, on a bar for each stretch of its coverage (a pause of more than 24 hours starts a new one). Hover or tap a dot for the headline, click it to read the article.
Source lean:leftcenterright
Source leans by Media Bias/Fact Check.
Results
2 articles mention clinical trial and vaccine in the last 7 days (Oct 20 to Oct 26).
| Article | |||
|---|---|---|---|
| The Guardian | ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial showsThe Guardian Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way Get our new political email , free app or daily news podcast A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show. The vaccine, intismeran, is custom-made to target genetic mutations unique to an individual’s melanoma. It is the first individualised cancer vaccine to show positive results in a phase III clinical trial . Continue reading... | 0.50● | |
| The Guardian | Controversial US-backed vaccine trial in African newborns haltedThe Guardian Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’ The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It was “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.” Continue reading... | 0.75● |
Source leans by Media Bias/Fact Check.
Narrow further
Other keywords in the matching articles: the share of them that mention each, with the number of articles.
No other keyword appears in more than one of the matching articles.
Coverage by source
The share of each source's stories in the last 7 days that match the query, from left to right. Sort the table to reorder the bars.
Source lean:leftcenterright
Source leans by Media Bias/Fact Check.
| The Guardian | 0.3% | 2 | 710 |
Coverage by lean
The share of stories that match the query, in the last 7 days, averaged over the outlets of each political lean with at least 3 stories. The groups differ in size, so a single outlet weighs more in the smaller ones.
- Left-leaning1 of 15 sources
- <0.1%
- Least biased0 of 8 sources
- 0.0%
- Right-leaning0 of 15 sources
- 0.0%
Lean index −3.6: covered more by left-leaning outlets
Each outlet at its MBFC bias score, from −10 (far left) to +10 (far right), as high as the share of its stories that match the query. The lean index is the average score of the outlets covering it, weighted by that share.
lean indexour sources' average (+0.4)leftcenterright
Bias scores by Media Bias/Fact Check.
Source leans based on ratings by Media Bias/Fact Check.